
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is de... Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.35 | 13.7795275591 | 2.54 | 3.06 | 2.45 | 2555074 | 2.75125352 | CS |
4 | 2.2211 | 332.052623711 | 0.6689 | 3.06 | 0.6303 | 12644889 | 2.3945668 | CS |
12 | 2.13 | 280.263157895 | 0.76 | 3.06 | 0.5052 | 4111277 | 2.35002445 | CS |
26 | 1.79 | 162.727272727 | 1.1 | 3.06 | 0.5052 | 2093633 | 2.27782597 | CS |
52 | 1.45 | 100.694444444 | 1.44 | 3.06 | 0.5052 | 1131773 | 2.19165 | CS |
156 | 1.858 | 180.03875969 | 1.032 | 3.18 | 0.5052 | 1246551 | 1.89608216 | CS |
260 | -8.75 | -75.1718213058 | 11.64 | 23.639 | 0.5052 | 855164 | 3.03106441 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions